drugset / Trial / NCT02744937

Continuing Low Dose Aspirin Before Prostate Biopsy

NCT02744937 ↗

Phase 4 Unknown 150 enrolled National Taiwan University Hospital
RandomizedParallel-groupSingle-blindDiagnostic

Summary

Objectives: To determine whether TRUS-guided prostate biopsy performed in patients continuing low-dose aspirin (LDA) is associated with a greater incidence, duration, and severity of bleeding complications. Eligibility: Men over 40-year-old with an elevated serum prostate-specific antigen level and/or abnormal digital rectal examination findings are candidates for PB. Design of trial Prospective Randomized Trial Study treatment: Continuing low-Dose aspirin before transrectal prostate biopsy Primary endpoint: The incidence, duration, and severity of bleeding complications Statistical analysis and sample size estimation: Fisher's exact test or chi-square test will be used to explore the differences between two groups for categorical variables, and Student t-test will be used for continuous variables. Under the assumption of a difference of 25% of bleeding complications in each group, with α=0.05 and power=0.80, 60 subject are needed in each arm. Assuming the drop-out rate to be 20%, the targeted recruit number is 150 in total.

Timeline

Start
2016-04
Primary completion
2019-03
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule — —

Indications

No indication recorded.